Search results
The goal is to understand the regulatory history and compliance of a company's products and research before entering into an agreement. This document discusses important areas of due diligence for companies considering partnering or acquiring another company's pharmaceutical or biologic products.
Emerging Life Sciences Companies Deskbook: Author: Morgan, Lewis & Bockius: Edition: 2: Publisher: Morgan, Lewis & Bockius, 2008 : Export Citation: BiBTeX EndNote RefMan
12 Emerging Life Sciences Companies Deskbook The following is a detailed outline of various issues to consider when spinning out a new venture. Reasons for Spinning Out A. To free the Company from its parent’s resource allocation and planning decisions and other constraints that may not be consistent with its health and growth
There is increased scope and significance of FDA regulatory issues/safety concerns; new pricing/reimbursement issues; and an expansion of the number of, and competition for, life science companies. The following outline sets forth many of such issues.
Life Sciences Emerging Markets Index: Poised for a new paradigm of growth. First-mover opportunities for life sciences companies and investors. At the beginning of 2021, JLL Research expanded its lens on life sciences to capture the qualities that define a new set of emerging life sciences markets.
16 Emerging Life Sciences Companies Deskbook Chapter 3 CORPORATE gOVERnAnCE ISSuES Corporate governance is a combination of (i) principles, (ii) policies, and (iii) procedures designed to enable the board of directors to manage the Company in accordance with duties owed to stockholders and other Company stakeholders.
As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside an abundance of exciting opportunities. The pharmaceutical and contract outsourcing space has shifted, with new trends emerging that will shape the future of this rapidly changing industry.
